| 证券代码 | EVAR.O |
| 证券名称 | Lombard Medical Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2014-04-25 |
| 首发价格(元) | 11 USD |
| 首发数量(股) | 5000000 |
| 首发募资额(元) | 55,000,000.00 USD |
| 首发主承销商 | Barclays Capital Inc,Jefferies LLC |
| 货币单位 | USD |
| 公司名称 | Lombard Medical, Inc. |
| 注册地址 | Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, Cayma |
| 办公地址 | 4 Trident Park, Didcot, Oxfordshire, United Kingdom |
| 成立日期 | 2013-01-14 |
| 董事会主席 | - |
| 公司属地 | Cayman Islands 开曼群岛（英属） |
| 公司网址 | www.lombardmedical.com |
| 电话 | +44 (1235) 750-800 |
| 传真 | +44 (1235) 750-879 |
| 公司简介 | Lombard Medical, Inc. is a medical technology company specializing in developing, manufacturing, and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms. Company's highest revenue product, currently Aorfix, is the only AAA stent-graft approved by the FDA and Japanese Ministry for Labor, Health and Welfare for the treatment of AAAs with angulation at the neck of the aneurysm of up to 90 degrees. |